Trial reportThe Journal of allergy and clinical immunology2020
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.
Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- The case for an Epstein-Barr virus vaccine: Lessons from its link to systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026Review
- Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease.Arthritis care & research · 2026Article
- Single-cell Unperturbed Activation Profiling by mass cytometry capturesFrontiers in immunology · 2026Article
- Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease.Lupus science & medicine · 2025Article
- Review
- Age-Associated B Cells in Autoimmune Diseases: Pathogenesis and Clinical Implications.Clinical reviews in allergy & immunology · 2025Review
- Single-cell mass cytometry in immunological skin diseases.Frontiers in immunology · 2024Review
- Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals.Frontiers in medicine · 2024Article
- Ancestry-based differences in the immune phenotype are associated with lupus activity.JCI insight · 2023Article
- Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease.BMC rheumatology · 2023Article
- Pathogenesis of autoimmune disease.Nature reviews. Nephrology · 2023Review
- The modifying influence of HLA class II DQB1∗06:02 on theGenes & diseases · 2023Article
- COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.Journal of medical virology · 2023Article
- Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone.Clinical rheumatology · 2022Review
- Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.Allergy · 2022Article
- Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus.Journal of autoimmunity · 2022Article
- Increased Circulating Cytokines Have a Role in COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
- The Prevalence and Clinical Relevance of the DFS Immunofluorescence Staining Pattern in a Large ANA-Positive Cohort.Frontiers in medicine · 2022Article
- The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives.Journal of inflammation research · 2022Review
- Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease.Antibodies (Basel, Switzerland) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAutoimmune diseases comprise a spectrum of illnesses and are on the rise worldwide. Although antinuclear antibodies (ANAs) are detected in many autoimmune diseases, up to 20% of healthy women are ANA-positive (ANA+) and most will never develop clinical symptoms. Furthermore, disease transition is higher among ANA+ African Americans compared with ANA+ European Americans.
objectiveWe sought to determine the immune features that might define and prevent transition to clinical autoimmunity in ANA+ healthy individuals.
methodsWe comprehensively phenotyped immune profiles of African Americans and European Americans who are ANA-negative (ANA-) healthy, ANA+ healthy, or have SLE using single cell mass cytometry, next-generation RNA-sequencing, multiplex cytokine profiling, and phospho-signaling analyses.
resultsWe found that, compared with both ANA- and ANA+ healthy individuals, patients with SLE of both races displayed T-cell expansion and elevated expression of type I and II interferon pathways. We discovered a unique immune signature that suggests a suppressive immune phenotype and reduced CD11C
conclusionsWe propose that this novel immune signature identified in ANA+ healthy European Americans may protect them from T-cell expansion, heightened activation of interferon pathways, and disease transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.